Influence of metabolic control in patients with refractory diabetic macular edema treated with Ozurdex
نویسندگان
چکیده
منابع مشابه
Effect of Intravitreal Dexamethasone Implant (Ozurdex®) in the Glycemic Control of Patients with Diabetic Macular Edema
Purpose: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex®) in the glycemic control of patients with diabetic macular edema. Methods: Ten patients with diabetic macular edema received an intravitreal injection (IVI) of dexamethasone implant (DEX implant, Ozurdex®). Glycated haemoglobin (HbA1C) is analyzed before and three months after IVI. The real-time glycemic readings ar...
متن کاملEvaluation of the Incidence of Macular Edema in Patients with Multiple Sclerosis Treated with Fingolimod
Purpose: To determine the incidence of macular edema in patients with MS treated with 0.5 mg Fingolimod. Methods: In this prospective descriptive-analytic study a total of 115 patients were enrolled. Patients underwent an ophthalmologic examination before starting the treatment. In the fourth month after starting the treatment for each patient, regardless of whether or not being marked, the oph...
متن کاملRefractory Diabetic Macular Edema
Diabetic macular edema (DME) is arguably one of the most important challenges in ophthalmology. Macular edema refractory to laser photocoagulation remains the most prevalent cause of untreatable vision loss in diabetes and is responsible for visual disability in millions of people worldwide. The lack of an effective therapeutic solution accounts for the range of interventions proposed. These in...
متن کاملPreliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema
BACKGROUND To evaluate the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex®; Allergan Inc, Irvine, CA, USA) in patients with persistent diabetic macular edema (DME) over a 6-month follow-up period. METHODS Seventeen patients (20 eyes) affected by DME were selected. The mean age was 67 + 8 years, and the mean duration of DME was 46.3 + 18.6 months. The eligibility criteri...
متن کاملCombined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema
PURPOSE To investigate the effectiveness and safety of combined phacoemulsification and dexamethasone intravitreal implant in patients with cataract and diabetic macular edema. METHODS In this two-center, retrospective, single-group study, the charts of 16 consecutive patients who underwent combined phacoemulsification and intravitreal dexamethasone implant were retrospectively reviewed. Thes...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Ophthalmologica
سال: 2017
ISSN: 1755-375X
DOI: 10.1111/j.1755-3768.2017.01566